on Theranexus (EPA:ALTHX)
Theranexus Announces Its Cash Position as of September 30, 2024
Theranexus, a company specializing in the treatment of rare neurological diseases, has published its cash position at the end of the third quarter of 2024. The company's cash position stands at €1.9 million, compared to €1.8 million as of June 30, 2024. This increase includes the 2024 Research Tax Credit of €785,000.
CEO Mathieu Charvériat highlights the company's commitment to the European registration of their new treatment for Niemann-Pick C disease, and the launch of phase 3 for Batten disease. Theranexus continues to explore opportunities with industrial partners to develop its products in lucrative markets.
The cash horizon is maintained until the end of the first quarter of 2025.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news